Welcome!

News Feed Item

Weightmasters Reveal Successful Results from Clinical Trials on Natural Appetite Suppressant, Opriimo

LONDON, January 23, 2014 /PRNewswire/ --

The recent BBC report on January 3rd revealed shocking figures of obesity quadrupling to nearly one billion in the developing world since the 1980s. 64% of adults are now classified as overweight or obese in the UK. With high levels of cheap convenience food available, and the increasing numbers of overweight Brits on the increase, Weightmasters have revealed successful results from clinical trials on their Natural Appetite Suppressant, Opriimo. (http://www.bbc.co.uk/news/health-25576400)

Opriimo is a revolutionary NEW weight management solution. It's a medical device and Natural Appetite Suppressant proven for weight management and the supportive treatment of excess weight. Unlike its closest comparable forms of Gastric Surgery, it's totally non-invasive, and available without hospital stay or prescription.

The effectiveness and tolerability of Opriimo has been investigated through three different clinical trials. All three were placebo-controlled, randomised, double-blind crossover studies. The clinical studies involved subjects, undergoing a series of methods over a 12 week period. The premise of these studies was to establish the ingredient, Alginate's effects towards weight reduction, satiation (appetite suppression) and the regulation of appetite.

Summarised results of Clinical Trials:

Alginate (a natural sponge, similar to seaweed), expands in the stomach. Radiological tests have demonstrated that the alginate solids remain in the stomach for up to 8 hours. (Krakamp et al 2000).

The sponges meet with the stomach wall and stimulate the receptors, which transmit a feeling of satiation (fullness), usually within 20-30 minutes of eating. (Schusdziarra 1996).

Where the capsules were taken 20-30 minutes before meals, excellent or favourable pre-satiation (fullness before eating) was achieved in 85 % of all participants during studies. (Willmen et al 1999).

Clinical Trial 1: The Investigation into the satiation effect of Alginate bodies. (Willmen 2002)

Undertaken to determine the satiation effect of Alginate bodies, 46 subjects were assessed where randomly selected subjects were given the Alginate (active group), while others given a placebo. The Results were significant in favour of the active group given Alginate. No clinically relevant side effects were observed.

Clinical Trial 2: The Investigation into significant weight reduction by stimulation of satiation sensors. (Willmen 2002)

Undertaken to determine the effectiveness of Alginate for weight loss and Satiation. 139 subjects took part in this investigation over 12 weeks. They took 3 x 3 capsules before main meals. Subjects given Alginate (active group) showed a more significant weight reduction (of up to 9.4Kg) compared to those taking the placebo. Additionally, satiation scores were significantly higher and fewer subjects dropped out of the trial from the active group.

Clinical Trial 3: Investigation into the regulation of appetite. (Willmen 2002)

Undertaken to determine the effectiveness of Alginate for the regulation of appetite. 25 subjects took part in this investigation. This was a mixed male / female group, aged between 18-70, all were normal weight. Randomly some subjects were given the Alginate capsules 3 x 3 per day (the active group), while others given a placebo. Subject groups were assessed regarding the calories consumed and saved. Results were statistically significant in favour of the active group. The calculation of the amount of food into calories showed that the participants consumed an average reduction of 158 less calories per day. Calculated on a yearly basis this calorie reduction equates to 57670 Kcal with a weight loss of 8Kg.

Additionally the reduction of appetite was 82.5 % in the active group, plus significantly less food was consumed and the appetite was lower. The differences between the groups were significant in favour of those taking Alginate (active group). No clinically relevant side effects were observed.

From the results of the three different clinical trials, the product has been proven as an effective Natural Appetite Suppressant for weight management and the supportive treatment of excess weight. It has been awarded CE product certification and approval from MHRA under EU Medical Device directives.

The results of the clinical trials have been summarised for ease of reading. The full clinical reports from the trials are available on request from [email protected]

About Opriimo:

Opriimo is a revolutionary new medical device designed to help people eat less, feel full and manage weight. It's totally non-invasive, so no surgery is required. There are no complicated diets to follow, and it is clinically proven.

Opriimo also comes with full 1:1 support from a personal weight management consultant.

  • Certified Medical Device
  • Clinically Proven
  • Non Invasive (No Surgery Required)
  • No Complicated Diets to follow
  • Includes 1:1 support from your own personal weight management consultant

Because of the nature of the product, Opriimo is not suitable for all, and some qualification criteria apply.

For more details, contact Weightmasters on +44(0)208-619-0025 or email [email protected].

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lead...
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
SYS-CON Events announced today that Daiya Industry will exhibit at the Japanese Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Ruby Development Inc. builds new services in short period of time and provides a continuous support of those services based on Ruby on Rails. For more information, please visit https://github.com/RubyDevInc.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
As businesses evolve, they need technology that is simple to help them succeed today and flexible enough to help them build for tomorrow. Chrome is fit for the workplace of the future — providing a secure, consistent user experience across a range of devices that can be used anywhere. In her session at 21st Cloud Expo, Vidya Nagarajan, a Senior Product Manager at Google, will take a look at various options as to how ChromeOS can be leveraged to interact with people on the devices, and formats th...
First generation hyperconverged solutions have taken the data center by storm, rapidly proliferating in pockets everywhere to provide further consolidation of floor space and workloads. These first generation solutions are not without challenges, however. In his session at 21st Cloud Expo, Wes Talbert, a Principal Architect and results-driven enterprise sales leader at NetApp, will discuss how the HCI solution of tomorrow will integrate with the public cloud to deliver a quality hybrid cloud e...
Is advanced scheduling in Kubernetes achievable? Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, will answer these questions and demonstrate techniques for implementing advanced scheduling. For example, using spot instances ...
SYS-CON Events announced today that Yuasa System will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Yuasa System is introducing a multi-purpose endurance testing system for flexible displays, OLED devices, flexible substrates, flat cables, and films in smartphones, wearables, automobiles, and healthcare.
SYS-CON Events announced today that Taica will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Taica manufacturers Alpha-GEL brand silicone components and materials, which maintain outstanding performance over a wide temperature range -40C to +200C. For more information, visit http://www.taica.co.jp/english/.
As hybrid cloud becomes the de-facto standard mode of operation for most enterprises, new challenges arise on how to efficiently and economically share data across environments. In his session at 21st Cloud Expo, Dr. Allon Cohen, VP of Product at Elastifile, will explore new techniques and best practices that help enterprise IT benefit from the advantages of hybrid cloud environments by enabling data availability for both legacy enterprise and cloud-native mission critical applications. By rev...
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
Organizations do not need a Big Data strategy; they need a business strategy that incorporates Big Data. Most organizations lack a road map for using Big Data to optimize key business processes, deliver a differentiated customer experience, or uncover new business opportunities. They do not understand what’s possible with respect to integrating Big Data into the business model.
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, will discuss how they b...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...